Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE
Abstract Introduction Primary results of the JADE DARE trial (NCT04345367) demonstrated that abrocitinib was superior to dupilumab in reducing the signs and symptoms of moderate-to-severe atopic dermatitis (AD). This post hoc analysis evaluated the efficacy and safety of abrocitinib in patients with...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-02-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-024-01320-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849769201622843392 |
|---|---|
| author | Jonathan I. Silverberg Eric L. Simpson Andrew E. Pink Stephan Weidinger Gary Chan Pinaki Biswas Claire Clibborn Erman Güler |
| author_facet | Jonathan I. Silverberg Eric L. Simpson Andrew E. Pink Stephan Weidinger Gary Chan Pinaki Biswas Claire Clibborn Erman Güler |
| author_sort | Jonathan I. Silverberg |
| collection | DOAJ |
| description | Abstract Introduction Primary results of the JADE DARE trial (NCT04345367) demonstrated that abrocitinib was superior to dupilumab in reducing the signs and symptoms of moderate-to-severe atopic dermatitis (AD). This post hoc analysis evaluated the efficacy and safety of abrocitinib in patients with moderate-to-severe AD who were responders or nonresponders to dupilumab using various definitions of response. Methods Data included dupilumab-treated patients from JADE DARE who switched to abrocitinib 200 mg when enrolled in the ongoing JADE EXTEND trial (NCT03422822). For this analysis, various response criteria at Week 26 of JADE DARE were defined post hoc based on Investigator’s Global Assessment (IGA), Eczema Area and Severity Index (EASI), Peak Pruritus Numerical Rating Scale (PP-NRS), and Dermatology Life Quality Index (DLQI) scores or responses. Efficacy was analyzed at Week 12 of JADE EXTEND based on patients’ fulfillment of the various response criteria at Week 26 of JADE DARE. EASI scores and percentage changes from baseline in EASI and PP-NRS at Week 26 in JADE DARE were compared with the corresponding scores and percentage changes at Week 12 in EXTEND. Safety was assessed. Results Of 365 dupilumab-treated patients in JADE DARE, 316 were enrolled in JADE EXTEND and 312 received abrocitinib 200 mg. Most dupilumab responders for IGA, EASI, PP-NRS, and DLQI at DARE Week 26 maintained their responses 12 weeks after switching to abrocitinib, while a considerable proportion of IGA, EASI, PP-NRS, or DLQI dupilumab nonresponders gained response after switching to abrocitinib. Lower EASI scores and greater percentage changes from baseline in EASI and PP-NRS scores were observed with abrocitinib at EXTEND Week 12 than with dupilumab at DARE Week 26. No new safety signals were observed. Conclusion Abrocitinib 200 mg may be an effective treatment option for patients with moderate-to-severe AD who do not achieve an optimal response with dupilumab treatment. Clinical Trial Registration Clinicaltrials.gov: NCT04345367 (JADE DARE) and NCT03422822 (JADE EXTEND). |
| format | Article |
| id | doaj-art-2ac4dcf76b864938a6ed9c15ce4fa203 |
| institution | DOAJ |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-2ac4dcf76b864938a6ed9c15ce4fa2032025-08-20T03:03:29ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-02-0115236738010.1007/s13555-024-01320-ySwitching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DAREJonathan I. Silverberg0Eric L. Simpson1Andrew E. Pink2Stephan Weidinger3Gary Chan4Pinaki Biswas5Claire Clibborn6Erman Güler7The George Washington University School of Medicine and Health SciencesOregon Health and Science UniversitySt. John’s Institute of Dermatology, King’s College LondonUniversity Hospital Schleswig-HolsteinPfizer Inc.Pfizer Inc.Pfizer Ltd.Pfizer Inc.Abstract Introduction Primary results of the JADE DARE trial (NCT04345367) demonstrated that abrocitinib was superior to dupilumab in reducing the signs and symptoms of moderate-to-severe atopic dermatitis (AD). This post hoc analysis evaluated the efficacy and safety of abrocitinib in patients with moderate-to-severe AD who were responders or nonresponders to dupilumab using various definitions of response. Methods Data included dupilumab-treated patients from JADE DARE who switched to abrocitinib 200 mg when enrolled in the ongoing JADE EXTEND trial (NCT03422822). For this analysis, various response criteria at Week 26 of JADE DARE were defined post hoc based on Investigator’s Global Assessment (IGA), Eczema Area and Severity Index (EASI), Peak Pruritus Numerical Rating Scale (PP-NRS), and Dermatology Life Quality Index (DLQI) scores or responses. Efficacy was analyzed at Week 12 of JADE EXTEND based on patients’ fulfillment of the various response criteria at Week 26 of JADE DARE. EASI scores and percentage changes from baseline in EASI and PP-NRS at Week 26 in JADE DARE were compared with the corresponding scores and percentage changes at Week 12 in EXTEND. Safety was assessed. Results Of 365 dupilumab-treated patients in JADE DARE, 316 were enrolled in JADE EXTEND and 312 received abrocitinib 200 mg. Most dupilumab responders for IGA, EASI, PP-NRS, and DLQI at DARE Week 26 maintained their responses 12 weeks after switching to abrocitinib, while a considerable proportion of IGA, EASI, PP-NRS, or DLQI dupilumab nonresponders gained response after switching to abrocitinib. Lower EASI scores and greater percentage changes from baseline in EASI and PP-NRS scores were observed with abrocitinib at EXTEND Week 12 than with dupilumab at DARE Week 26. No new safety signals were observed. Conclusion Abrocitinib 200 mg may be an effective treatment option for patients with moderate-to-severe AD who do not achieve an optimal response with dupilumab treatment. Clinical Trial Registration Clinicaltrials.gov: NCT04345367 (JADE DARE) and NCT03422822 (JADE EXTEND).https://doi.org/10.1007/s13555-024-01320-yAbrocitinibAtopic dermatitisDupilumabJAK-1 selective inhibitorNonrespondersResponders |
| spellingShingle | Jonathan I. Silverberg Eric L. Simpson Andrew E. Pink Stephan Weidinger Gary Chan Pinaki Biswas Claire Clibborn Erman Güler Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE Dermatology and Therapy Abrocitinib Atopic dermatitis Dupilumab JAK-1 selective inhibitor Nonresponders Responders |
| title | Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE |
| title_full | Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE |
| title_fullStr | Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE |
| title_full_unstemmed | Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE |
| title_short | Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE |
| title_sort | switching from dupilumab to abrocitinib in patients with moderate to severe atopic dermatitis a post hoc analysis of efficacy after treatment with dupilumab in jade dare |
| topic | Abrocitinib Atopic dermatitis Dupilumab JAK-1 selective inhibitor Nonresponders Responders |
| url | https://doi.org/10.1007/s13555-024-01320-y |
| work_keys_str_mv | AT jonathanisilverberg switchingfromdupilumabtoabrocitinibinpatientswithmoderatetosevereatopicdermatitisaposthocanalysisofefficacyaftertreatmentwithdupilumabinjadedare AT ericlsimpson switchingfromdupilumabtoabrocitinibinpatientswithmoderatetosevereatopicdermatitisaposthocanalysisofefficacyaftertreatmentwithdupilumabinjadedare AT andrewepink switchingfromdupilumabtoabrocitinibinpatientswithmoderatetosevereatopicdermatitisaposthocanalysisofefficacyaftertreatmentwithdupilumabinjadedare AT stephanweidinger switchingfromdupilumabtoabrocitinibinpatientswithmoderatetosevereatopicdermatitisaposthocanalysisofefficacyaftertreatmentwithdupilumabinjadedare AT garychan switchingfromdupilumabtoabrocitinibinpatientswithmoderatetosevereatopicdermatitisaposthocanalysisofefficacyaftertreatmentwithdupilumabinjadedare AT pinakibiswas switchingfromdupilumabtoabrocitinibinpatientswithmoderatetosevereatopicdermatitisaposthocanalysisofefficacyaftertreatmentwithdupilumabinjadedare AT claireclibborn switchingfromdupilumabtoabrocitinibinpatientswithmoderatetosevereatopicdermatitisaposthocanalysisofefficacyaftertreatmentwithdupilumabinjadedare AT ermanguler switchingfromdupilumabtoabrocitinibinpatientswithmoderatetosevereatopicdermatitisaposthocanalysisofefficacyaftertreatmentwithdupilumabinjadedare |